ArticleJournal of magnetic resonance imaging : JMRI2026
Comparison of Single-Breath and Multi-Breath Xe-MRI in the Longitudinal Assessment of Treatment in Children With Cystic Fibrosis.
Article in Journal of magnetic resonance imaging : JMRI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundElexacaftor/tezacaftor/ivacaftor (ETI) is a current standard therapy for pediatric cystic fibrosis (CF). Multiple-breath washout PURPOSE: To compare MBW Xe-MRI and single-breath Xe-MRI in a small pediatric CF cohort at 1, 6, 12, and 24 months post-ETI initiation. STUDY TYPE: Prospective longitudinal cohort study. SUBJECTS: 14 participants (7 female, median age 15.5 [14, 17] years) with CF undergoing ETI. FIELD STRENGTH/SEQUENCE: Xe-MRI using a gradient echo sequence at 3T. ASSESSMENT: A total of 12 participants completed MBW Xe-MRI, single-breath Xe-MRI, and PFTs (spirometry, N STATISTICAL TESTS: Longitudinal changes were analyzed using a linear mixed-effects model (fixed effect: time, random intercept: participant). Significance via ANOVA F-test, p < 0.05. Intra-class correlation coefficients (ICC) were used to quantify between- and within-subject variability.
resultsData completeness (total number of acquired data points divided by expected data points across 14 participants, 4 visits) was ≥ 75%. While PFTs/VDP remained stable over 24 months (ICC ≥ 0.93; linear mixed-effects model of time effect for ppFEV DATA
conclusionCoV EVIDENCE LEVEL: 1. STAGE OF TECHNICAL EFFICACY: 2.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.